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adapted if needed. 724 CT features were calculated using 
radiomics software. To test if features were different for 
EGFR+, KRAS+ or WT patients one way ANOVA (initially 
without correction for multiple testing) was performed using 
a 5% significance level. A pair-wise comparison (t-test) 
identified significantly different groups. 
 
Results: 51 EGFR+, 47 KRAS+ and 32 WT patients were 
included. 41 features were significantly different between 
EGFR+, KRAS+ and WT patients. One feature is a first order 
gray-level statistics feature (7% of feature subgroup total), 
two are gray-level co-occurrence matrix based (9%), two 
gray-level size-zone matrix based (18%), one Laplacian-of-
Gaussian transform based (0.5%) and 35 are wavelet 
transform based features (7%). Statistics for the significant 
features are shown in Table 1. One easy to interpret 
significantly different feature for EGFR+ compared to WT 
patients was the median Hounsfield Unit (HU). EGFR+ 
patients had a median HU which is on average 54±23 HU 
higher compared to WT patients, see Figure 1. KRAS+ 
patients did not have a significantly different median HU 
compared to EGFR+ or WT patients. 
 
 
 
 
Conclusion: We showed that there are differences in 
radiomic CT features between EGFR+, KRAS+ and WT NSCLC. 
The next step will be to externally validate (work in progress) 
a robust radiomic signature, based on standard CT imaging. 
Also this allows to monitor radiomic signature evolvement 
under treatment. 
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Hadron therapy is an advanced technique in the field of 
radiotherapy that makes use of charged particles such as 
protons and carbon ions. The inverted depth-dose profile and 
the sharp dose fall-off after the Bragg peak offered by 
charged particle beams allow for a more precise localization 
of the radiation dosage to the tumor as compared to the 
conventional used photons. As a consequence, the 
surrounding healthy tissue receives a much lower dose. 
Besides this ballistic advantage, the use of high-linear energy 
transfer (LET) carbon ion beams offers also a biological 
advantage, i.e. a higher relative biological effectiveness 
(RBE) as compared to conventional low-LET photon therapy.  
Carbon ion radiation is thus more effective in inducing DNA 
damage, cell cycle arrest and cell death, thereby accounting 
for highly lethal effects, even in tumors that are resistant to 
X-ray irradiation. 
The response of an irradiated cell depends on the dose, dose-
rate, radiation quality, the lapse between the radiation-
induced stress and the analysis, and the cell type. In this 
context, genome-wide studies can contribute in exploring 
differences in signaling pathways and to unravel 'high-LET-
specific' genes. Several studies within SCK•CEN and outside 
have already compared changes in gene expression induced 
by different radiation qualities. Overall, the number of 
differentially expressed genes as well as the magnitude of 
(dose-dependent) gene expression changes was found to be 
more pronounced after irradiation with particle beams.  
Currently, the Radiobiology Unit of SCK•CEN is deeply 
investigating the effect of low- and high-LET radiation on the 
gene expression of different cancer cell lines in vitro. Our 
results clearly demonstrate a dose-dependent downregulation 
in several genes involved in cell migration and motility after 
carbon ion irradiation. A higher number of genes as well as 
more pronounced changes in their expression levels were 
found after carbon ion irradiation compared to X-rays. 
Further research are currently investigating whether the 
observed molecular changes also influence the cellular 
'behavior' after irradiation in terms of cell migration and 
motility after irradiation, since these are prominent 
characteristics of cancer progression and metastasis. 
Assessing both the risks and advantages of high-LET 
irradiation can contribute to the study of the biological 
effect on the tumor and will lead to further acceptance and 
improvement of the clinical outcome of hadron therapy.  
Acknowledgements: This work is partly supported by the 
Federal Public Service in the context of the feasibility study 
‘Application of hadrontherapy in Belgium’, which is part of 
action 30 of the Belgian cancer plan. Carbon ion irradiation 
experiments (P911-H) were performed at the Grand 
Accélérateur National d'Ions Lourds (Caen, France). 
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Particle therapy as cancer treatment, with either protons or 
heavier ions, provide a more favourable dose distribution 
compared to x-rays. While the physical characteristics of 
particle radiation have been the aim of intense research, less 
focus has been on the actual biological responses particle 
irradiation gives rise to. Protons and high LET radiation have 
a higher radiobiological effect (RBE), but RBE is a complex 
quantity, depending on both biological and physical 
parameters. One of the central questions in particle therapy 
is whether the tumor and the normal tissue has a differential 
RBE due to the difference in α/β ratio. Most of the data to 
enlighten this is in vitro data, and there is very limited in 
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vivo data available, although this is a more appropriate 
reflection of the complex biological response.  
RBE is often established as measured by cell death, but 
emerging evidence also demonstrate an altered response in 
the surviving cells. This is both evident for high LET 
radiation, but also for proton radiation. This differential 
biological effect is not only relevant in the tumour, but also 
in the normal tissue. Current research in particle radiobiology 
is, in addition to the RBE, focusing on the molecular tissue 
response, and on the signalling pathways. Gene expression 
response in a panel of primary human fibroblasts, established 
from patients with known response to xray radiation in 
regards to late tissue damage, irradiated in vitro with 
different radiation qualities, has evaluated the effect of 
particle irradiation at different positions in the beam. This 
enlightens the heterogeneity in patient response to proton 
irradiation, individual biological variations and the 
differential effect of proton irradiation. This presentation 
will focus on the available experimental data on normal 
tissue response after irradiation with protons or heavier ions.  
Supported by grants from the Danish Cancer Society 
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Many technological developments attempt to reduce dose to 
normal tissues in order to reduce normal tissue damage. 
However, optimal use of such technologies requires 
knowledge of mechanisms underlying normal tissue damage. 
Therefore, normal tissue effects were studied using highly 
accurate proton irradiation to different regions and volumes 
in various rat organs. 
Rats were irradiated using high-energy protons. Collimator 
design was based on X-ray imaging (spinal cord), MRI (parotid 
gland) or CT scans (heart, lung) of age, sex and weight 
matched rats. This typically resulted in 2-4% uncertainty in 
irradiated volume of that organ. For partial irradiation of the 
spinal cord an in-line X-ray imager was used to yield a 
positioning accuracy of 0.1 mm. Finally, non-uniform 
irradiations were facilitated by sequential use of different 
collimators. Hind leg paralysis, breathing frequency chances 
and salivary flow rate and tissue histo-pathology were used to 
assess organ response. 
Spinal cord: Next to irradiated volume, low doses surrounding 
small volumes with a high dose effects were found to strongly 
impact the tolerance dose. In addition, the tolerance dose 
strongly depended on the shape of the dose distribution, 
independent of irradiated volume. Taken together this 
indicates that irradiated volume is not good predictor of 
toxicity. However, a model including tissue repair originating 
from non-irradiated tissue over a limited distance could 
explain the observed effects. Taken together these results 
suggest that regeneration plays an important role in the 
response of the spinal cord. 
Parotid gland: We demonstrated that the response of the 
parotid gland critically depends on dose to its stem cells, 
mainly located in its major ducts. The importance of this 
anatomical location was confirmed in a retrospective analysis 
of clinical data. A prospective clinical trial to validate this 
finding is in progress. 
Lung: Volume dependent mechanisms of lung toxicities were 
observed, where high volumes with low dose limiting early 
vascular/inflammatory responses inducing pulmonary 
hypertension and consequential cardiac problems, whereas 
low volumes displayed high or even no dose limiting late 
fibrotic response. Moreover, inclusion of the heart in the 
irradiation field strongly enhanced early lung responses. 
In summary, using high-precision proton irradiation of rat 
organs we elucidated several mechanisms and critical targets 
for normal tissue damage. In general we found that, rather 
than dose to the organ, the development of toxicity strongly 
related to dose to functional sub-structures within the organ 
or even in other organs. In general, in more parallel 
organized tissues it seems that a high dose to a small volume 
is better that a low dose to a large volume. Maintaining or 
enhancing the regenerating potential of the normal tissue 
seems warranted to further optimize radiation therapy. 
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Treatment of verterbral metastasis can be compex, involving 
medical treatment, radiotherapy, suregry or newer technique 
such as thermal ablation and vertebroplasty. The purpose of 
vertebral metastasis treatment is to rapidly improve the 
quality of life of the patients and to restore the mechanical 
properties of the spinal column and to a lesser extend to 
prevent local tumor growth.  
Minimally invasive treatment,such as vertebroplasty, 
combined or not, with thermal ablation fulfill all these 
purposes with minimal impact on the patient’s quality of life.  
Vertebroplasty is efficient in contolling the patient’s pain in 
89.7% at 1 month and 86.9% at 6 months (ref 1).  
Restoration of the mechanical properties of the spinal column 
is obtaind in 100% of cases after successful vertebroplasty 
(ref 2)  
When combined with thermal ablation (RFA or Cryoablation) 
the local reccurence rate is very low (ref 3)  
While radiation therapy remains the mainstay in the 
treatment of vertebral metastasis, it does not improve the 
stability of the vertebral column. A complimentary surgery is 
often necessary to ensure stability of the treated vertebra. 
Minimalliy invasive procedure such as thermal ablation 
combined with vertebroplasty do offer immediate pain 
control in addition to local tumor control and restoration of 
mechanical stability with a minimal impact on the patient’s 
quality of life. 
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Radiotherapy is a well-established treatment for painful 
vertebral metastases. Multiple prospective studies report 
pain response rates of 50 to 90%. Based on randomized 
studies, 8 Gy in a single fraction is the standard of care for 
painful uncomplicated bone metastases. Despite the lack of a 
dose response relationship for pain control, there is good 
rationale for dose escalation with the aim to improve upon 
existing rates of local tumour control and pain control. 
Stereotactic body radiotherapy is ideally suited to safely 
escalate the dose and improve tumour control. In order to 
optimize the potential of SBRT, adequate patient selection 
and specific technical considerations should be taken into 
account.  
PATIENT SELECTION  
Several considerations should be taken into account before 
delivering SBRT for vertebral metastases. A first 
consideration is the life expectancy of the patient, which 
should be evaluated with validated scoring systems (e.g. NRF 
score, Recursive partitioning analysis index, PRISM). Patients 
with a short life expectancy in need for palliative 
radiotherapy should be managed with short effective 
radiotherapy courses. In patients with longer life expectancy 
local control might be an important end point potentially 
